kynurenine has been researched along with Parkinson Disease in 42 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 6.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 2.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Parkinson's disease is a common progressive neurodegenerative disorder presenting with characteristic motor symptoms." | 2.53 | Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System. ( Fülöp, F; Majláth, Z; Toldi, J; Vécsei, L, 2016) |
| " Although levodopa continues to be the gold standard of symptomatic efficacy for treatment of the cardinal motor features, its chronic use is associated with potentially disabling motor complications." | 2.46 | Medical treatment of Parkinson's disease: today and the future. ( Gárdián, G; Vécsei, L, 2010) |
| "L-kynurenine is a central compound of this pathway since it can change to the neuroprotective agent kynurenic acid or to the neurotoxic agent quinolinic acid." | 2.43 | Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. ( Németh, H; Toldi, J; Vécsei, L, 2006) |
| " To exploit possibilities of TDO inhibitory treatment, development of further selective TDO inhibitor compounds with good bioavailability features and models adequately replicating PD symptoms of systemic origin should be prioritized." | 1.62 | Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease. ( Boros, FA; Vécsei, L, 2021) |
| "The kynurenine (KYN) pathway plays an important role in degrading molecules responsible for oxidative stress in the central nervous system (CNS), but can also have neurotoxic effects." | 1.56 | Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease. ( Iwaoka, K; Kato, K; Maeda, T; Otsuka, C; Takahashi, K; Terayama, Y; Yamahara, K, 2020) |
| "The pathogenesis of Parkinson's disease (PD) remains to be elucidated." | 1.48 | Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease. ( Chang, KH; Chen, CM; Cheng, ML; Huang, CY; Tang, HY; Wu, YR, 2018) |
| "L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective drug in the symptomatic treatment of Parkinson's disease, but chronic use is associated with L-DOPA-induced dyskinesia in more than half the patients after 10 years of treatment." | 1.46 | Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Faergeman, NJ; Gramsbergen, JB; Havelund, JF; Heegaard, NHH; Stenager, E, 2017) |
| "In 22 patients with Parkinson's disease (PD) and in 11 age-matched controls, serum and cerebrospinal fluid (CSF) neopterin concentrations were measured by ELISA." | 1.31 | Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. ( Fuchs, D; Leblhuber, F; Widner, B, 2002) |
| "In untreated patients with Parkinson's disease (PD), the total (free and conjugated) serotonin (5-HT) and dopamine (DA) concentrations in the cerebrospinal fluid decreased significantly." | 1.29 | Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. ( Abe, T; Hamato, H; Takahashi, J; Takahashi, S; Tohgi, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 16 (38.10) | 24.3611 |
| 2020's | 16 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Boros, FA | 1 |
| Vécsei, L | 11 |
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Endepols, H | 1 |
| Zlatopolskiy, BD | 1 |
| Zischler, J | 1 |
| Alavinejad, N | 1 |
| Apetz, N | 1 |
| Vus, S | 1 |
| Drzezga, A | 1 |
| Neumaier, B | 1 |
| Venkatesan, D | 1 |
| Iyer, M | 1 |
| S, RW | 1 |
| Narayanasamy, A | 1 |
| Kamalakannan, S | 1 |
| Valsala Gopalakrishnan, A | 1 |
| Vellingiri, B | 1 |
| Qin, W | 1 |
| Shi, Y | 1 |
| Chen, W | 1 |
| Jia, X | 1 |
| Asakawa, T | 1 |
| Martins, LB | 1 |
| Silveira, ALM | 1 |
| Teixeira, AL | 1 |
| Török, N | 1 |
| Maszlag-Török, R | 1 |
| Molnár, K | 1 |
| Szolnoki, Z | 1 |
| Somogyvári, F | 1 |
| Boda, K | 1 |
| Tanaka, M | 2 |
| Klivényi, P | 4 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Chen, P | 1 |
| Geng, X | 1 |
| Hajihassani, A | 1 |
| Nourazarian, A | 1 |
| Nikanfar, M | 1 |
| Laghousi, D | 1 |
| Khaki-Khatibi, F | 1 |
| Iwaoka, K | 1 |
| Otsuka, C | 1 |
| Maeda, T | 1 |
| Yamahara, K | 1 |
| Kato, K | 1 |
| Takahashi, K | 2 |
| Terayama, Y | 1 |
| Toldi, J | 7 |
| Bai, JH | 1 |
| Zheng, YL | 1 |
| Yu, YP | 1 |
| Heilman, PL | 1 |
| Wang, EW | 1 |
| Lewis, MM | 1 |
| Krzyzanowski, S | 1 |
| Capan, CD | 1 |
| Burmeister, AR | 1 |
| Du, G | 1 |
| Escobar Galvis, ML | 1 |
| Brundin, P | 1 |
| Huang, X | 1 |
| Brundin, L | 1 |
| Pingale, T | 1 |
| Gupta, GL | 1 |
| Behl, T | 1 |
| Kaur, I | 1 |
| Sehgal, A | 1 |
| Singh, S | 1 |
| Bhatia, S | 1 |
| Al-Harrasi, A | 1 |
| Zengin, G | 1 |
| Bumbu, AG | 1 |
| Andronie-Cioara, FL | 1 |
| Nechifor, AC | 1 |
| Gitea, D | 1 |
| Bungau, AF | 1 |
| Toma, MM | 1 |
| Bungau, SG | 1 |
| Havelund, JF | 1 |
| Andersen, AD | 1 |
| Binzer, M | 1 |
| Blaabjerg, M | 1 |
| Heegaard, NHH | 1 |
| Stenager, E | 1 |
| Faergeman, NJ | 1 |
| Gramsbergen, JB | 1 |
| Robertson, DS | 1 |
| Chang, KH | 1 |
| Cheng, ML | 1 |
| Tang, HY | 1 |
| Huang, CY | 1 |
| Wu, YR | 1 |
| Chen, CM | 1 |
| van den Brink, WJ | 1 |
| Palic, S | 1 |
| Köhler, I | 1 |
| de Lange, ECM | 1 |
| Sorgdrager, FJH | 1 |
| Vermeiren, Y | 1 |
| Van Faassen, M | 1 |
| van der Ley, C | 1 |
| Nollen, EAA | 1 |
| Kema, IP | 1 |
| De Deyn, PP | 1 |
| Lewitt, PA | 1 |
| Li, J | 1 |
| Lu, M | 1 |
| Beach, TG | 1 |
| Adler, CH | 1 |
| Guo, L | 1 |
| Amara, AW | 1 |
| Standaert, DG | 1 |
| Obál, I | 1 |
| Majláth, Z | 2 |
| Luan, H | 1 |
| Liu, LF | 1 |
| Meng, N | 1 |
| Tang, Z | 1 |
| Chua, KK | 1 |
| Chen, LL | 1 |
| Song, JX | 1 |
| Mok, VC | 1 |
| Xie, LX | 1 |
| Li, M | 1 |
| Cai, Z | 1 |
| Mazarei, G | 1 |
| Leavitt, BR | 1 |
| Fülöp, F | 2 |
| Lim, CK | 1 |
| Fernández-Gomez, FJ | 1 |
| Braidy, N | 1 |
| Estrada, C | 1 |
| Costa, C | 1 |
| Costa, S | 1 |
| Bessede, A | 1 |
| Fernandez-Villalba, E | 1 |
| Zinger, A | 1 |
| Herrero, MT | 1 |
| Guillemin, GJ | 1 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Gárdián, G | 1 |
| Szabó, N | 1 |
| Kincses, ZT | 1 |
| Zádori, D | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Hartai, Z | 1 |
| Janaky, T | 1 |
| Penke, B | 1 |
| Dux, L | 1 |
| Németh, H | 1 |
| Sternberg, EM | 1 |
| Van Woert, MH | 1 |
| Young, SN | 1 |
| Magnussen, I | 1 |
| Baker, H | 1 |
| Gauthier, S | 1 |
| Osterland, CK | 1 |
| Tohgi, H | 2 |
| Abe, T | 2 |
| Takahashi, S | 2 |
| Takahashi, J | 2 |
| Hamato, H | 2 |
| Stone, TW | 1 |
| Widner, B | 1 |
| Leblhuber, F | 1 |
| Fuchs, D | 1 |
| Beal, MF | 2 |
| Matson, WR | 2 |
| Storey, E | 1 |
| Milbury, P | 2 |
| Ryan, EA | 1 |
| Ogawa, T | 2 |
| Bird, ED | 2 |
| Myers, RH | 1 |
| Saso, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of 12 Weeks Vitamin D Supplementation Combined With Physical Activity on Blood and Functional Parameters and Quality of Life in Parkinson's Disease Patients Treated With Deep Brain Stimulation[NCT04768023] | 50 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for kynurenine and Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Topics: 3-Hydroxyanthranilic Acid; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Levodopa; Parki | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Research progress on the kynurenine pathway in the prevention and treatment of Parkinson's disease.
Topics: Central Nervous System; Humans; Inflammation; Kynurenine; Parkinson Disease | 2023 |
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Cytokines; Humans; Huntington Disease; Infl | 2020 |
Current and emerging therapeutic targets for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Humans; Kynurenine; Melanins; Mitochondria; Par | 2021 |
The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
Topics: Biomarkers; Central Nervous System; Gastrointestinal Microbiome; Humans; Kynurenine; Metabolic Netwo | 2021 |
Access to the CNS: Biomarker Strategies for Dopaminergic Treatments.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine Agents; Drug Development; Humans; Hypothalamo- | 2018 |
Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxins.
Topics: Dopamine; Glutamic Acid; Humans; Kynurenine; Mental Disorders; Neuroprotective Agents; Neurotoxins; | 2014 |
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynure | 2015 |
Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Kynurenine; Levodo | 2016 |
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Topics: Animals; Humans; Kynurenine; Parkinson Disease | 2017 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
Medical treatment of Parkinson's disease: today and the future.
Topics: Dopamine Agonists; Humans; Kynurenine; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2010 |
Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach.
Topics: Antiparkinson Agents; Humans; Kynurenine; Levodopa; Parkinson Disease; Tryptophan | 2011 |
Kynurenines in Parkinson's disease: therapeutic perspectives.
Topics: Animals; Humans; Kynurenine; Neuroprotective Agents; Parkinson Disease | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Quinolinic Acid; Recepto | 2006 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
1 trial available for kynurenine and Parkinson Disease
| Article | Year |
|---|---|
Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Aged; Carbidopa; Clinical Trials as Topic; Drug Therapy, Com | 1980 |
22 other studies available for kynurenine and Parkinson Disease
| Article | Year |
|---|---|
Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Parkinson Disease; Tryptophan; Tryptophan | 2021 |
Imaging of cerebral tryptophan metabolism using 7-[
Topics: Animals; Disease Models, Animal; Fluorine Radioisotopes; Hippocampus; Kynurenine; Male; Melatonin; O | 2022 |
Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.
Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; India; Kynurenine; Mutation; Parkinson Disease | 2022 |
The Involvement of Kynurenine Pathway in Neurodegenerative Diseases.
Topics: Alzheimer Disease; Cross-Sectional Studies; Humans; Kynurenine; Neurodegenerative Diseases; Parkinso | 2023 |
Single Nucleotide Polymorphisms of Indoleamine 2,3-Dioxygenase 1 Influenced the Age Onset of Parkinson's Disease.
Topics: Biomarkers; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Parkinson Disease; Polymorphis | 2022 |
Kynurenine and Beta-Alanine Serum Levels are Associated with the Expression of Wnt Pathway Genes in Patients with Parkinson's Disease.
Topics: Biomarkers; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Wnt Signaling Pathway | 2023 |
Impaired metabolism of kynurenine and its metabolites in CSF of parkinson's disease.
Topics: Aged; Case-Control Studies; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-1 | 2020 |
Urinary kynurenine as a biomarker for Parkinson's disease.
Topics: Biomarkers; Cognitive Dysfunction; Humans; Kynurenine; Parkinson Disease; Triglycerides | 2021 |
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
Topics: Biomarkers; Humans; Kynurenine; Parkinson Disease; Substantia Nigra; Tryptophan | 2020 |
Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
Topics: Adult; Aged; Antiparkinson Agents; Biomarkers; Denmark; Dyskinesia, Drug-Induced; Female; Humans; Ky | 2017 |
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Kynurenine; Male; Metabolome; Metabolomics; Middle Aged | 2018 |
Age- and disease-specific changes of the kynurenine pathway in Parkinson's and Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Female; Humans; Kynurenine; Male; Middle Aged; Parkinson Disease | 2019 |
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glutathione; Humans; Kynurenine; Male; Mass Spec | 2013 |
Metabolomics and the search for biomarkers in Parkinson's disease.
Topics: Female; Humans; Kynurenine; Male; Oxidative Stress; Parkinson Disease | 2013 |
LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biomarkers; Chromatography, Liquid; Drosophila melanogaster; Fatty Acids; | 2015 |
Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease.
Topics: Adaptation, Physiological; Aged; Brain; Erythrocytes; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2005 |
Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration.
Topics: Aged; Dopamine; Humans; Hydroxyindoleacetic Acid; Kynurenine; Levodopa; Middle Aged; Parkinson Disea | 1993 |
Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms.
Topics: 5-Hydroxytryptophan; Humans; Hydroxyindoleacetic Acid; Kynurenine; Middle Aged; Parkinson Disease; R | 1993 |
Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.
Topics: Aged; Chromatography, High Pressure Liquid; Female; Humans; Immunity, Cellular; Kynurenine; Male; Ne | 2002 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Kynurenine pathway abnormalities in Parkinson's disease.
Topics: Aged; Autopsy; Brain; Female; Humans; Kynurenine; Male; Parkinson Disease; Tryptophan; Tyrosine | 1992 |